Association for Molecular Pathology, et al., Petitioners v. Myriad Genetics, Inc., et al.

Decided June 13, 2013. Clarence Thomas delivered the opinion of the Court.

Docket 12-398 · 569 U.S. 576 (2013) · Cited 363 times

Holding

A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring.

The Court’s statement of the holding, from the opinion’s syllabus. The syllabus is prepared by the Reporter of Decisions and is not part of the opinion of the Court — read the official opinion for authority.

How the Justices voted

Decided 9–0.

“Concurring” means agreeing with the outcome; any split shown is the Court’s judgment, not each Justice’s reasoning. Source: the Supreme Court Database (Spaeth et al.), Washington University.

Precedents cited

Supreme Court decisions this opinion relies on, ordered by how often it cites each. Cases in our collection link through; others are named.

• Diamond v. Chakrabarty · 447 U.S. 303 (1980)
• Mayo Collaborative Services v. Prometheus Laboratories, Inc. · 566 U.S. 66 (2012)
• Funk Bros. Seed Co. v. Kalo Inoculant Co. · 333 U.S. 127 (1948)
• MedImmune, Inc. v. Genentech, Inc. · 549 U.S. 118 (2007)
• J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc. · 534 U.S. 124 (2001)
• Hartranft v. Wiegmann · 121 U.S. 609 (1887)

Cited by

Later Supreme Court opinions in our collection that cite this case.

• Halo Electronics, Inc. v. Pulse Electronics, Inc. · 579 U.S. 93 (2016)

Official text

Read the official opinion (U.S. Reports, govinfo.gov)

Explore from here

Clarence Thomas’s profile · All Supreme Court opinions · The Supreme Court

Source: Supreme Court of the United States, slip opinions (2013). Citation count from the Free Law Project’s CourtListener bulk data. Data last verified 2026-07-03. Informational only; verify against the primary source before relying. Not a consumer report (FCRA).